JNJ-39393406

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H18F2N6O3
Molecular Weight	416.3814
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C(=O)CCN1N=C(NC2=CC3=C(OC(F)(F)O3)C=C2)N=C1C4=CC=NC=C4

InChI

InChIKey=IURMHZBQEYNQOH-UHFFFAOYSA-N

InChI=1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25)

HIDE SMILES / InChI

Molecular Formula	C19H18F2N6O3
Molecular Weight	416.3814
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/2029086 | https://www.ncbi.nlm.nih.gov/pubmed/29185480

JNJ-39393406 is a positive allosteric alpha-7 nicotinic acetylcholine receptor modulator. It was under development for the treatment of smoking cessation, schizophrenia, Alzheimer's disease, but development for these indications was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.	2013 Jan	22766391
Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia.	2018 May	29185480

Patents

Sample Use Guides

In Vivo Use Guide

200 mg/day (100 mg b.i.d.).

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:31:43 UTC 2023` Edited by `admin` on `Sat Dec 16 10:31:43 UTC 2023`
Record UNII	T930SOU82P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

JNJ-39393406

Common Name

English

1H-1,2,4-TRIAZOLE-1-PROPANAMIDE, 3-((2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)AMINO)-N,N-DIMETHYL-5-(4-PYRIDINYL)-

Systematic Name

English

Code System Code Type Description

CAS

953428-73-4